Empower Pharmacy Lawsuit 2026: Eli Lilly Case Status and What Consumers Should Know
Quick Answer
- This is real, active federal litigation between Eli Lilly and Empower Pharmacy over compounded tirzepatide, not a scam text about pouch settlement money.
- There is no consumer settlement fund and no payout tied to this case; it is a corporate trademark and unfair competition dispute, not a certified consumer class action.
- No trial date has been set following the April 29, 2026 partial dismissal ruling in the U.S. District Court for the Southern District of Texas.
If you searched “Empower Pharmacy lawsuit” because you used a compounded GLP-1 drug from the company, here is the direct answer. Eli Lilly sued Empower Pharmacy, not the other way around, and no patient claims fund exists.
The case centers on whether Empower’s compounded tirzepatide products, sold as alternatives to Lilly’s Mounjaro and Zepbound, violated trademark and consumer protection laws. A judge trimmed some claims in April 2026 but let the core dispute continue.
This article covers exactly where the Lilly-Empower case stands, what separate FDA safety issues have surfaced at Empower’s facilities, and what patients should watch for. One detail buried in most coverage: Empower has racked up FDA warning letters going back to 2017, well before this lawsuit ever started.
The Facts
| Case | Eli Lilly and Company v. Empower Clinic Services, LLC, d/b/a Empower Pharmacy |
| Court | U.S. District Court for the Southern District of Texas, Case No. 4:25-cv-03464 |
| Status | Partially dismissed April 29, 2026; core unfair competition claims proceeding; in discovery |
| Fund Size | Not applicable. No settlement fund exists; this is not a certified consumer class action |
| Est. Per Person | Not applicable. There is no individual patient payout tied to this case |
| Claim Deadline | Not applicable. No claims process exists for consumers in this litigation |
| Administrator | Not applicable |
| Proof Needed | Not applicable to this case. Separate FDA recall notices may apply if you received a specific recalled lot |
Is the Empower Pharmacy lawsuit real?
Yes, it’s a real, active federal case, but it’s a fight between two companies, not a consumer class action you can join for money.
Eli Lilly and Company filed suit against Empower Clinic Services, doing business as Empower Pharmacy, in the U.S. District Court for the Southern District of Texas. The case number is 4:25-cv-03464.
If you saw social media posts or ads implying you can file for a payout from “the Empower Pharmacy lawsuit,” that’s not accurate as of September 2026. This case involves trademark, Lanham Act, and state unfair competition claims brought by Lilly, not injury claims brought by patients seeking compensation.
Key Takeaway: Eli Lilly is suing Empower Pharmacy over compounded drug sales, and no patient settlement or claims process exists in this specific case.
How much money is involved in the Empower Pharmacy lawsuit?
Not yet determined, and there is no per-person payout because this is not a certified class action with a settlement fund.
The financial numbers that are verified relate to Empower’s business, not any damages awarded or settled. Empower’s revenue more than doubled from $119 million in 2022 to $377 million in 2024 as GLP-1 shortages fueled demand for compounded alternatives. Separately, Eli Lilly’s Zepbound and Mounjaro brought in about $36 billion for the company in 2025.
What’s confirmed versus not confirmed on money:
| Item | Status |
|---|---|
| Empower’s 2022 to 2024 revenue growth | Confirmed: $119 million to $377 million |
| Eli Lilly’s 2025 GLP-1 revenue | Confirmed: approximately $36 billion combined for Zepbound and Mounjaro |
| Damages sought by Lilly | Not yet confirmed publicly as a specific dollar figure |
| Any consumer payout | Not applicable, no such claims process exists in this case |
Reality Check: No one will text or call you offering an “Empower Pharmacy settlement check,” because no consumer settlement has been reached in this litigation. If you received a specific recalled product, any refund or reporting process comes directly from the FDA or Empower’s own recall notice, never through a third party charging a fee to file on your behalf.
How do you check if your Empower Pharmacy product was recalled?
Empower Pharmacy voluntarily recalled a lot of testosterone, roughly 8,000 vials, in May 2025, citing quality assurance concerns after contamination was found in a preparation area the previous year.
If you’re concerned about a specific product, the process is straightforward and does not involve this lawsuit.
Steps to check on a possible Empower recall:
- Locate your product’s lot number, printed on the vial or packaging.
- Check current FDA recall postings for Empower Clinic Services or Empower Pharmacy.
- Contact your prescribing provider if you have safety concerns about a compounded drug.
- Report any adverse reaction directly to the FDA’s MedWatch program.
- Keep your product packaging and receipts in case you need to reference lot numbers later.
- Do not rely on this Lilly-Empower lawsuit for recall information, since it’s a separate, unrelated legal matter.
What is Eli Lilly’s lawsuit against Empower Pharmacy actually about?
Eli Lilly alleges Empower Pharmacy sold unauthorized, unapproved versions of Mounjaro and Zepbound, the brand-name tirzepatide drugs, and misled consumers about their safety.
Lilly first filed suit on April 1, 2025, in the U.S. District Court for the District of New Jersey. The company voluntarily dismissed that case and refiled on July 25, 2025, in the Southern District of Texas, where Empower is headquartered.
The lawsuit accuses Empower of trademark violations under the Lanham Act, plus state-level consumer protection and unfair competition claims. Lilly specifically targeted Empower’s “Tirzepatide ODT,” an orally dissolving tablet version the company calls an untested knockoff with no clinical data supporting its effectiveness.
Empower has pushed back publicly, framing the case as part of Lilly’s broader campaign against compounding pharmacies rather than a case specific to its own conduct.
Key Takeaway: This lawsuit is fundamentally about trademark and marketing claims between two companies, not a product liability case brought by injured patients.
What did the judge rule on April 29, 2026?
U.S. District Court Judge Sim Lake dismissed Eli Lilly’s federal trademark claims and Texas unfair competition claims, but allowed unfair competition allegations under other states’ laws to move forward.
The judge found Lilly had not shown lost sales or irreparable harm tied to Empower’s alleged false advertising, which undercut the trademark and Texas-specific claims. The ruling did not end the case. Core allegations tied to Empower’s marketing practices in other states are proceeding.
What survived versus what was dismissed, as verified:
| Claim type | Outcome |
|---|---|
| Federal trademark claims | Dismissed |
| Texas unfair competition claims | Dismissed |
| Unfair competition claims under other states’ laws | Allowed to proceed |
Empower characterized the ruling as striking down central allegations and called it an important step forward for patients and doctors. Lilly has not publicly conceded the case is weakened, and litigation over the surviving claims continues.
Is there a class action against Empower Pharmacy for patients?
Not confirmed as an active, certified class action specific to Empower Pharmacy patient injuries as of September 2026.
Separately, a nationwide class action has been filed over unapproved oral tirzepatide products sold through telehealth brands, but that case names OpenLoop Health Inc., Triad Rx Buyer LLC, and Triad Rx Inc. as defendants, not Empower Pharmacy directly. Some legal-marketing sites describe broader “Empower Pharmacy lawsuit” claims involving individual patients who allege infections or adverse reactions, but a confirmed, court-certified class specific to Empower was not verified in the sources checked for this article.
If you believe you were harmed by an Empower-compounded product, here’s what is and isn’t confirmed:
- Confirmed: Multiple FDA warning letters cite sterility and manufacturing violations at Empower facilities.
- Confirmed: At least one voluntary product recall occurred in May 2025.
- Not yet confirmed: Any certified nationwide class action for patient injuries specifically against Empower Pharmacy.
- Not yet confirmed: Any settlement fund or claims administrator tied to patient injury claims.
What has the FDA said about Empower Pharmacy’s safety record?
The FDA has issued multiple warning letters to Empower Pharmacy since 2017, citing sterility failures, inadequate quality testing, and non-pharmaceutical grade ingredients.
Two warning letters were issued in April 2025 alone, one to Empower’s Sam Houston Parkway facility citing that products “intended or expected to be sterile were prepared, packed, or held under insanitary conditions,” and a second to another Houston plant over current good manufacturing practice concerns.
Empower’s FDA enforcement history, as documented:
| Date | Finding |
|---|---|
| May 2017 | First FDA warning letter; invalid prescriptions and sterile drug quality issues |
| October 2021 | Second warning letter; inadequate adverse event investigation system |
| August 2022 | FDA finds non-pharmaceutical and food-grade ingredients used in injectable drugs |
| December 2023 | More sterile production problems; unapproved ingredient suppliers |
| August 2024 | FDA finds a sterile drug batch released despite positive microbial growth |
| April 2, 2025 | Two warning letters citing sterility and CGMP violations |
| November 2025 (inspection) | Investigators find staff failing to disinfect items in production areas; inadequate stress testing of aseptic processes |
Key Takeaway: Empower’s FDA violation history spans nearly a decade and is documented independently of the Eli Lilly trademark lawsuit.
Has Empower Pharmacy issued any recalls?
Yes, Empower voluntarily recalled a lot of roughly 8,000 vials of testosterone in May 2025, citing a lack of quality assurance after contamination was discovered in a preparation area the year before.
Empower told reporters its own finished-product testing showed no contamination and said the recall was issued out of caution rather than because the FDA required it. The company has not publicly confirmed additional recalls beyond this lot as of the sources checked for this article.
If you were prescribed a compounded drug from Empower and are concerned about a specific batch, checking the lot number against current FDA recall postings is the direct way to confirm whether your product was affected.
Is there a multidistrict litigation (MDL) for Empower Pharmacy cases?
Not yet confirmed. Some law firms have publicly stated they are investigating whether MDL consolidation would be appropriate for compounding pharmacy cases involving GLP-1 drugs, but no formal MDL transfer order specific to Empower has been confirmed as of September 2026.
MDL consolidation, if it happens, would combine similar federal cases before one judge for shared pretrial proceedings, similar to how other mass tort cases are handled. That process has not been finalized here, so treat any claim of an active Empower MDL as unconfirmed until a formal transfer order is issued by the Judicial Panel on Multidistrict Litigation.
Why did other drugmakers sue compounding pharmacies too?
Eli Lilly is not alone in this legal strategy. Novo Nordisk filed lawsuits against 12 defendants, including several pharmacies, on August 4, 2025, targeting compounders selling versions of semaglutide, the active ingredient in Ozempic and Wegovy.
This wave of litigation followed the FDA removing tirzepatide and semaglutide from its drug shortage lists in 2024, which restricted mass compounding of both drugs. Before the shortage ended, pharmacies were legally permitted to compound copies to meet patient demand.
Think of it like a store return policy that changes overnight. What was allowed under a temporary shortage exception suddenly became a legal gray area once supply caught up, and companies like Lilly moved quickly to enforce the new boundary.
What happens to patients using compounded GLP-1 drugs from Empower now?
Patients can generally continue using compounded medications prescribed to them unless a specific recall or safety alert applies to that product.
This lawsuit does not, on its own, require patients to stop using previously dispensed medication. It also does not create any refund or compensation process for patients simply because they purchased a compounded product during the period covered by the lawsuit.
What to actually watch for, if you’re a current or former Empower patient:
- FDA recall notices tied to specific lot numbers.
- Updates from your prescribing provider about product availability.
- Separate, confirmed patient injury litigation, distinct from the Lilly trademark case, if and when it’s verified.
What Happens Next
- April 29, 2026 (already happened): Judge Sim Lake issues partial dismissal, keeping core unfair competition claims alive.
- Ongoing: Discovery phase in the Eli Lilly v. Empower case, with depositions and document exchange expected to continue into 2027 according to legal analysts tracking the case.
- Expected, no confirmed date: Additional court filings on the surviving state-law claims as the case moves toward further motions or trial scheduling.
- Unconfirmed, under investigation: Possible MDL consolidation for compounding pharmacy litigation broadly, not yet finalized.
- Ongoing: Continued FDA inspections of Empower facilities following the November 2025 findings, with agency follow-up expected but not yet confirmed as complete.
Frequently Asked Questions
Is Empower Pharmacy being sued by Eli Lilly?
Yes, Eli Lilly filed suit against Empower Clinic Services, doing business as Empower Pharmacy, over compounded tirzepatide products.
The case is pending in the U.S. District Court for the Southern District of Texas, case number 4:25-cv-03464.
Can patients join a lawsuit against Empower Pharmacy?
There is no confirmed, certified consumer class action against Empower Pharmacy specifically tied to patient injuries as of September 2026.
If you believe you were harmed by a compounded product, consulting an attorney about an individual claim is a separate path from this corporate trademark case.
Did a judge dismiss the Empower Pharmacy lawsuit?
Only part of it, on April 29, 2026.
Federal trademark claims and Texas unfair competition claims were dismissed, but unfair competition claims under other states’ laws are proceeding.
Is Empower Pharmacy still operating in 2026?
Yes, based on available reporting, Empower Pharmacy continues to operate as one of the largest 503B compounding facilities in the country while the lawsuit and FDA scrutiny continue.
No court order has been confirmed requiring the company to cease operations.
Was there an Empower Pharmacy product recall?
Yes, Empower voluntarily recalled roughly 8,000 vials of a testosterone lot in May 2025, citing quality assurance concerns following a contamination finding the prior year.
Check current FDA recall listings if you have concerns about a specific lot number.
How much did Empower Pharmacy make from GLP-1 drug sales?
Empower’s overall revenue grew from $119 million in 2022 to $377 million in 2024 as demand for compounded weight-loss drugs surged during the FDA-declared shortage period.
That figure reflects total company revenue, not GLP-1 sales specifically, based on available reporting.
Is there a trial date set for the Empower Pharmacy lawsuit?
No. As of September 2026, no trial date has been scheduled following the April 29, 2026 partial dismissal ruling.
The case remains in discovery, and legal analysts tracking it expect proceedings to continue into 2027.
What should I do if I had a bad reaction to a compounded drug from Empower?
Report the adverse event directly to the FDA’s MedWatch program and contact your prescribing provider.
This lawsuit does not currently offer a compensation path for individual patient injuries, so any personal claim would need to be pursued separately with an attorney’s guidance.
There’s no payout to chase here yet, and no deadline on your calendar tied to this specific case. If you’re a current or former Empower Pharmacy patient, checking FDA recall notices for your product’s lot number is the one concrete action worth taking today.
